Skip to search formSkip to main contentSkip to account menu

ACE910

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

emicizumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Faculty of 1000 evaluation for A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.
2017
2017
Elucidating the Excessive Pro-Coagulant Effect of a Sequence Identical Analogue to ACE910 in Combination with Bypassing Agents
Review
2016
Review
2016
Bispecific antibody mimicking factor VIII.
2015
2015
Enhanced Global Hemostatic Potentials with a Bispecific Antibody to Factors IXa and X (ACE910) in the Whole Blood By Rotation Thromboelastometry (ROTEM)
Background: ACE910, a humanized bispecific antibody to factor (F) IXa and FX mimicking the functions of FVIII, exerts tenase… 
2015
2015
[New hemophilia treatment employing a bispecific antibody to factors IXa and X].
Unmet needs of current hemophilia A treatment include the requirement for frequent intravenous infusions, inhibitor development… 
2015
2015
ACE910 Facilitates Its Hemostatic Effect with the Lower Concentration of Factor X Than That Required for Factor VIIa-Driven Coagulation
The hemostatic effect of bypassing agents such as recombinant (r) factor (F)VIIa and activated prothrombin complex concentrates… 
2014
2014
Safety and Prophylactic Efficacy Profiles of ACE910, a Humanized Bispecific Antibody Mimicking the FVIII Cofactor Function, in Japanese Hemophilia A Patients Both without and with FVIII Inhibitors…
Background: Although routine supplementation of exogenous factor VIII (FVIII) effectively prevents bleeding complications in… 
2014
2014
FVIII Heavy Chain Enhances Tenase Activity Induced By FVIIIa Mimicking Bispesific Antibody, ACE910
Background: ACE910, asymmetric bispecific monoclonal antibodies to activated factor IX (IXa) and factor X, mimics the cofactor… 
2014
2014
Non–antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity
While antibody engineering improves the properties of therapeutic antibodies, optimization of regions that do not contact… 
2012
2012
Generation of a Novel Bispecific Antibody (ACE910) Against Activated Factor IX and Factor X Mimicking the Function of Factor VIII Cofactor Activity
Abstract 1126 Exogenous factor VIII (FVIII) is used to reduce bleeding complications in patients with severe hemophilia A… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)